What makes North Carolina a leading life science hub?

Global Innovation Hub: North Carolina, USA

Tuesday, June 4  |  2:30 p.m.  |  Theater 4, Second Floor

Learn what North Carolina has to offer as a leading life science hub and why we're ranked a top place to do business.

Presented by:
Mary Hecht-Kissell
Director, Business Development, NCBiotech

Mary Hecht-Kissell is putting her extensive marketing background to work building relationships with life science companies all over the world. She previously worked for a medical device startup that was acquired by J&J, and enjoys helping others achieve success in the life sciences.

Add session to calendar

 

Innovative Models for Real World Evidence: Creating Value-Based Precision Health

Wednesday, June 5  |  1:45-2:45 p.m.  |  Room 116

Payers are evaluating provider and reimbursement policies, seeking value in precision health. This is shifting paradigms in precision health innovation, favoring models with strategic and agile approaches to discovery research, translation and implementation. These models emphasize partnerships and commitments around evidence thresholds upstream of data collection, and they are demonstrating the potential and promise of precision health for transforming clinical care.

During this session, Vital Innovation and Alva10 will present new and emerging pathways for generating this real world evidence, while Optum will highlight the payer perspective and role for researcher, industry and payer collaborations.

Moderated by:
Sara Imhof, Ph.D.
Senior Director, Precision Health, NCBiotech

Sara Imhof, Ph.D, oversees the North Carolina Precision Health Collaborative (NCPHC) within the North Carolina Biotechnology Center. The NCPHC facilitates a cohesive public-private coalition that leverages North Carolina’s vibrant life science ecosystem to foster research, enable providers, and engage industry to improve health outcomes and optimize resource utilization in North Carolina. Specific areas of focus for NCPHC include precision population health, pharmacogenomics, education and thought-leadership around the value proposition for precision health in an evolving healthcare system.

Add session to calendar

 

Technology-Based Economic Development: Evolving Models, Strategies and Finance Approaches

Wednesday, June 5  |  3:00 p.m.  |  Room 109AB

While life sciences directed technology-based economic development (TBED) organizations have multiplied over the last 40 years, their missions are similar and largely unchanged - to drive regional economic development in the life sciences. Many leading organizations have adopted roles as direct or indirect investors in innovation at all stages of development. These investments - ranging from traditional grants, loans and tax credits to equity vehicles, seeding public/private partnerships and other emerging investment models - are designed to grow their innovation pipelines and generate economic and financial returns for their primary funders.

Representatives from four of the nation’s premier life sciences TBED organizations will discuss the evolution of their models and their current approaches for delivering impact to their funders and constituents.

NCBiotech panelist:
Doug Edgeton, MPH, MBA
President and CEO, NCBiotech

Doug Edgeton brings extensive executive-level experience in health care, research park development, and business administration. Edgeton has managed both talent and facilities to create an ecosystem for organizational growth. He translates this experience to the leadership role at NCBiotech, where he targets state investment and staff expertise to help North Carolina’s life science companies grow, create jobs, and bring life-changing technologies to market.

Add session to calendar

 

Biotech’s Contribution to Innovation: Current and Future Drivers of Success

Tuesday, June 4 | 2:30-3:45 p.m. | 113ABC, Level 100

With their involvement in over 70% of the clinical pipeline — whether they partner, license or commercialize on their own – biotech companies continue to be the driving force behind innovation in drug development. This session will explore the current state of innovation within biotech companies and examine what is on the horizon for these companies. What are the critical success factors that will help them be best prepared to sustain their contribution to innovation and improvement in human health?

North Carolina Panelist:
Art Pappas
Managing Partner, Pappas Capital